Express News | Celcuity Inc Files for Mixed Shelf of up to $400 Mln - SEC Filing
LifeSci Capital Initiates Coverage on Celcuity With Outperform Rating, $27 Price Target
Celcuity (CELC) Upgraded to Buy: Here's Why
Is Celcuity (NASDAQ:CELC) A Risky Investment?
Earnings Call: Celcuity Reports Q2 Loss, Progresses on Gedatolisib Trials
Celcuity Inc. (CELC) Q2 2024 Earnings Call Transcript Summary
Celcuity Inc. (CELC) Q2 2024 Earnings Call Transcript
A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $23 to $39
Celcuity Is Maintained at Buy by Stifel
Express News | Celcuity Inc : Stifel Cuts Target Price to $39 From $40
Express News | Needham Reiterates Buy on Celcuity, Maintains $23 Price Target
Analysts Conflicted on These Healthcare Names: Verrica Pharmaceuticals (VRCA), Celcuity (CELC) and Bluebird Bio (BLUE)
Express News | Celcuity Inc : Jefferies Raises Target Price to $28 From $27
Optimistic Outlook for Celcuity's Gedatolisib in Phase III Trials Supports Buy Rating
Celcuity | 10-Q: Q2 2024 Earnings Report
Express News | Celcuity Shares Are Trading Lower. The Company Reported Q2 Financial Results
Earnings Flash (CELC) CELCUITY Reports Q2 Loss $-0.58, Vs. Street Est of $-0.55
Express News | Celcuity Q2 Net Income USD -23.7 Million
Express News | Celcuity Q2 Adjusted EPS USD -0.58 Vs. IBES Estimate USD -0.68
Express News | Celcuity Q2 EPS USD -0.62